Cargando…

The Efficacy of Levocarnitine Treatment in Relieving Fatigue in Patients with Cirrhosis but without Overt Hepatic Encephalopathy

OBJECTIVE: In the present study, we prospectively examined the efficacy of levocarnitine in relieving symptoms of fatigue in patients with cirrhosis but without overt hepatic encephalopathy. METHODS: Twenty-one cirrhotic patients who were able to undergo fatigue symptom evaluations at our institutio...

Descripción completa

Detalles Bibliográficos
Autores principales:	Abe, Kazumichi, Fujita, Masashi, Hayashi, Manabu, Takahashi, Atsushi, Ohira, Hiromasa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Japanese Society of Internal Medicine 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8666222/ https://www.ncbi.nlm.nih.gov/pubmed/34776465 http://dx.doi.org/10.2169/internalmedicine.7175-21

Ejemplares similares

Skeletal muscle volume loss among liver cirrhosis patients receiving levocarnitine predicts poor prognosis
por: Fujita, Masashi, et al.
Publicado: (2020)

Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia
por: Hayashi, Manabu, et al.
Publicado: (2018)

Changes in platelet levels and prognosis in patients with acute liver failure and late-onset hepatic failure
por: Hayashi, Manabu, et al.
Publicado: (2022)

Association of serum 25-hydroxyvitamin D levels with severe necroinflammatory activity and inflammatory cytokine production in type I autoimmune hepatitis
por: Abe, Kazumichi, et al.
Publicado: (2020)

Circulating complement factor H levels are associated with disease severity and relapse in autoimmune hepatitis
por: Hayashi, Manabu, et al.
Publicado: (2022)

Hepatitis B Virus Reactivation in a Patient with Nonalcoholic Steatohepatitis 41 Months after Rituximab-containing Chemotherapy
por: Hayashi, Manabu, et al.
Publicado: (2018)

Factors associated with hepatocellular carcinoma occurrence after HCV eradication in patients without cirrhosis or with compensated cirrhosis
por: Abe, Kazumichi, et al.
Publicado: (2020)

Association between serum ficolin-1 level and disease progression in primary biliary cholangitis
por: Hayashi, Manabu, et al.
Publicado: (2020)

Interleukin‐33/ST2‐Mediated Inflammation Plays a Critical Role in the Pathogenesis and Severity of Type I Autoimmune Hepatitis
por: Abe, Kazumichi, et al.
Publicado: (2019)

Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease
por: Abe, Kazumichi, et al.
Publicado: (2018)

Endogenous Endophthalmitis Associated with Pyogenic Liver Abscess Caused by Klebsiella pneumoniae
por: Fujita, Masashi, et al.
Publicado: (2019)

Intratumor Abscess in a Posttraumatic Hepatic Inflammatory Pseudotumor Spreading Out of the Liver
por: Hayashi, Manabu, et al.
Publicado: (2020)

Levocarnitine Use Is Associated With Improvement in Sarcopenia in Patients With Liver Cirrhosis
por: Hiramatsu, Akira, et al.
Publicado: (2019)

Prediction and prevention of the first episode of overt hepatic encephalopathy in patients with cirrhosis
por: Gairing, Simon J., et al.
Publicado: (2023)

Cortical signature of patients with HBV-related cirrhosis without overt hepatic encephalopathy: a morphometric analysis
por: Wu, Xiu, et al.
Publicado: (2015)

Huge Hepatocellular Carcinoma Treated with Radical Hepatectomy after Drug-eluting Bead Transarterial Chemoembolization
por: Fujita, Masashi, et al.
Publicado: (2019)

Sigmoid Colon Varices due to Massive Thrombosis of a Noncirrhotic Extrahepatic Portosystemic Shunt
por: Hayashi, Manabu, et al.
Publicado: (2020)

Interleukin-21 plays a critical role in the pathogenesis and severity of type I autoimmune hepatitis
por: Abe, Kazumichi, et al.
Publicado: (2016)

Significance of Levocarnitine Treatment in Dialysis Patients
por: Takashima, Hiroyuki, et al.
Publicado: (2021)

Overt Hepatic Encephalopathy Experienced by Individuals With Cirrhosis: A Qualitative Interview Study
por: Ladegaard Grønkjær, Lea, et al.
Publicado: (2018)

The Role of Presepsin in Diagnosing Infections in Patients with Liver Cirrhosis and Overt Hepatic Encephalopathy
por: Igna, Razvan, et al.
Publicado: (2022)

Anomalous Gray Matter Structural Networks in Patients with Hepatitis B Virus-Related Cirrhosis without Overt Hepatic Encephalopathy
por: Lv, Xiao-Fei, et al.
Publicado: (2015)

Albumin infusion may decrease the incidence and severity of overt hepatic encephalopathy in liver cirrhosis
por: Bai, Zhaohui, et al.
Publicado: (2019)

Reduced brain activity in female patients with non-alcoholic fatty liver disease as measured by near-infrared spectroscopy
por: Takahashi, Atsushi, et al.
Publicado: (2017)

Effects of sleep quality on non-alcoholic fatty liver disease: a cross-sectional survey
por: Takahashi, Atsushi, et al.
Publicado: (2020)

Effects of Levocarnitine Treatment on the Cardiac Function in Hemodialysis Patients
por: Maruyama, Takashi, et al.
Publicado: (2018)

Association of serum albumin level with incidence and mortality of overt hepatic encephalopathy in cirrhosis during hospitalization
por: Bai, Zhaohui, et al.
Publicado: (2019)

Usefulness of the Stroop Test in Diagnosing Minimal Hepatic Encephalopathy and Predicting Overt Hepatic Encephalopathy
por: Hanai, Tatsunori, et al.
Publicado: (2021)

Impaired brain glucose metabolism in cirrhosis without overt hepatic encephalopathy: a retrospective (18)F-FDG PET/CT study
por: Zhang, Weishan, et al.
Publicado: (2019)

Abnormal corpus callosum induced by overt hepatic encephalopathy impairs interhemispheric functional coordination in cirrhosis patients
por: Kuang, Yangying, et al.
Publicado: (2021)

Prediction of overt hepatic encephalopathy by the continuous reaction time method and the portosystemic encephalopathy syndrome test in clinically mentally unimpaired patients with cirrhosis
por: Wernberg, Charlotte W., et al.
Publicado: (2019)

Potential role of levocarnitine supplementation for the treatment of chemotherapy-induced fatigue in non-anaemic cancer patients
por: Graziano, F, et al.
Publicado: (2002)

Primary Prophylaxis of Overt Hepatic Encephalopathy: Is It Time to Consider It?
por: Faccioli, Jessica, et al.
Publicado: (2023)

Contrast uptake in primary hepatic angiosarcoma on gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging in the hepatobiliary phase
por: Hayashi, Manabu, et al.
Publicado: (2018)

Urinary metabolic profiling by (1)H NMR spectroscopy in patients with cirrhosis may discriminate overt but not covert hepatic encephalopathy
por: McPhail, Mark J. W., et al.
Publicado: (2016)

Altered Modular Organization of Functional Connectivity Networks in Cirrhotic Patients without Overt Hepatic Encephalopathy
por: Zheng, Gang, et al.
Publicado: (2014)

Disrupted Brain Intrinsic Networks and Executive Dysfunction in Cirrhotic Patients without Overt Hepatic Encephalopathy
por: Yang, Zhe-Ting, et al.
Publicado: (2018)

Predicting overt hepatic encephalopathy after TIPS: Value of three minimal hepatic encephalopathy tests
por: Ehrenbauer, Alena F., et al.
Publicado: (2023)

Overt hepatic encephalopathy in Italy: clinical outcomes and healthcare costs
por: Roggeri, Daniela Paola, et al.
Publicado: (2015)

Effect of levocarnitine administration in patients with chronic liver disease
por: Ohashi, Kazuki, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vi3eq8p68nqkh2qobk6ie152i9